International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

Lilly Announces a New, Citrate-Free Formulation of Taltz® (ixekizumab)

Lilly Press Release Graphic

Eli Lilly and Company announced on August 8 the availability of a new, citrate-free formulation of Taltz® (ixekizumab) injection 80 mg/mL. The new formula, approved by the United States Food and Drug Administration (FDA) in May 2022, contains the same active ingredient as the original formulation. Still, patients experience significantly less pain at the injection site. Existing Taltz patients will not need a new prescription and should not experience a gap in their therapy. The new formula is expected to be available, to new and existing patients, across the United States by the end of the month. The citrate-free formulation was also approved by the European Medicines Agency in December 2021, with several markets launching now and more anticipated in the coming months. IPC’s councilor, April Armstrong, MD, MPH, was quoted in the press release saying: “Today is an exciting milestone for the nearly 30 million people around the world who live with the challenging symptoms of these autoimmune diseases that affect the skin and joints. In my six years of prescribing Taltz, I have seen firsthand the significant impact Taltz has had for patients across multiple indications. The availability of Taltz as a citrate-free formulation represents an important advance in patient care that will allow more patients to experience less injection-site pain.”
.

Employees advance our mission with big ideas, unique perspectives, and the dedication to bring relief to millions around the world.
Categories
Tags
Recent Posts
BIOMAP Collaboration Update A Systemic Review on Biomarkers

BIOMAP Collaboration Update: A Systemic Review on Biomarkers

BMS Press Release Graphic

U.S. Food and Drug Administration Approves Sotyktu™(deucravacitinib)

Blog - Commentary - Alexander Egeberg - graphic

Commentary: Drug Survival Associated with Effectiveness and Safety of Treatment with Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients with Psoriasis

Also Read

2022 SPIN Congress Report Blog Graphic
Deepak Balak

Focus on Psoriasis: A Report from the 7th Congress of the Skin Inflammation & Psoriasis International Network (SPIN) Meeting

The Society of Investigative Dermatology (SID) Annual Meeting returned to an in-person format in 2022 for the first time in two years. The following congress report includes a summary of the Eugene Farber lecture, three IPC lectures, and seven IPC poster presentations, all with a focus on psoriasis. You can download the full report or read on for a brief look at some of the highlights.

Read More

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.